Ramiro Guerrero Purchases 46,620 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero acquired 46,620 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was acquired at an average price of $1.35 per share, for a total transaction of $62,937.00. Following the completion of the transaction, the director owned 735,701 shares in the company, valued at approximately $993,196.35. The trade was a 6.77% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

• On Thursday, August 27th, Ramiro Guerrero purchased 78,239 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero purchased 8,931 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Up 5.4%

NYSEAMERICAN:MAIA opened at $1.37 on Thursday. The company has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.43. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19. The stock has a market cap of $83.34 million, a price-to-earnings ratio of -2.21 and a beta of 0.25.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts forecast that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MAIA. Centric Wealth Management purchased a new stake in MAIA Biotechnology in the second quarter worth $1,107,000. Solas Capital Management LLC purchased a new position in MAIA Biotechnology during the second quarter valued at $4,364,000. Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at $741,000. Geode Capital Management LLC boosted its holdings in shares of MAIA Biotechnology by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after buying an additional 25,684 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology in the 4th quarter worth about $120,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.